Mr. Hugh Rogers reports

BIONXT SECURES FINAL PATENT GRANT FROM THE EURASIAN PATENT ORGANIZATION FOR SUBLINGUAL CLADRIBINE PLATFORM

The Eurasian Patent Organization (EAPO) has officially granted patent No. 051510 (issued Nov. 14, 2025).

The patent covers the sublingual delivery of anti-cancer drugs for the treatment of autoimmune and neurodegenerative diseases, including Bionxt's lead product candidate BNT23001, a sublingual thin-film formulation of cladribine for multiple sclerosis (MS). The patent grant provides protection across all eight EAPO member states (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan and Turkmenistan) representing a combined population of more than 200 million people. The patent is valid through June 14, 2043.

A key milestone for Bionxt's global IP (intellectual property) strategy

"The Eurasian patent grant marks a major milestone in our value creation and commercialization strategy," said Hugh Rogers, chief executive officer of Bionxt. "This is Bionxt's first national-level patent and it arrives at a pivotal time, with our two-week large-mass animal bioequivalence study currently under way. We expect meaningful catalysts in the coming weeks and months, including additional national patent grants, results from the animal study, and the launch of our human bioequivalence study. We are confident that these milestones will accelerate ongoing discussions with potential regional and global licencing partners."

Expanding global patent coverage

Bionxt continues to advance patent nationalization across key global pharmaceutical markets, including the European Union, where the European Patent Office (EPO) has issued an intention to grant and confirmed novelty, inventive step and industrial applicability. In the United States, a Track 1 priority filing is under way, while parallel nationalization efforts progress in Canada, Australia, New Zealand and Japan. Together, these regions represent some of the world's largest and most advanced pharmaceutical markets and form the foundation for Bionxt's commercialization and partnering initiatives.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange (under the symbol BNXT) and the OTC Markets (under the symbol BNXTF) and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.